Gjermund Henriksen

Dr. Gjermund Henriksen


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2004
Verified
Journal Article
Closed access
TPThorsten Poethko
Thorsten Poethko
MSMargret Schottelius
Margret Schottelius
GTGeorgette Thumshirn
Georgette Thumshirn
UHUlrich Hersel
Ulrich Hersel
MHMichael Herz
Michael Herz
HWHans-Jürgen Wester
Hans-Jürgen Wester

1 January 2013 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
ILIina Laitinen
Iina Laitinen
JNJohannes Notni
Johannes Notni
KPKarolin Pohle
Karolin Pohle
MRMartina Rudelius
Martina Rudelius
EFEliane Farrell
Eliane Farrell
MSMarkus Schwaiger
Markus Schwaiger
Expression of αvβ3 integrin is increased after myocardial infarction as part of the repair process. Increased expression of αvβ3 has been shown by molecular imaging with 18F-galacto-RGD in a rat model. The 68Ga-labelled RGD compounds 68Ga-NODAGA-RGD and 68Ga-TRAP(RGD)3 have high specificity and affinity, and may therefore serve as alternatives of 18F-galacto-RGD for integrin imaging.

28 March 2015 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
Behrooz Hooshyar YousefiBehrooz Hooshyar Yousefi
Behrooz Hooshyar Yousefi
BRBoris von Reutern
Boris von Reutern
DSDaniela Scherübl
Daniela Scherübl
AMAndré Manook
André Manook
MSMarkus Schwaiger
Markus Schwaiger
HWHans-Jürgen Wester
Hans-Jürgen Wester
Over the last decade, an increasing number of studies have been published on the use of amyloid-β (Aβ) PET imaging with different 18F-radiopharmaceuticals for clinical characterization of Alzheimer’s disease (AD) in different stages. However, distinct study cohorts and different quantification techniques allow only for an indirect comparison between the different tracers. Thus, the aim of this study was the direct intra-individual in vivo comparison of different Aβ-targeted radiopharmaceuticals for PET imaging, including the newly developed agent [18F]FIBT. A small group of four animals of a well-characterized APP/PS1 transgenic (tg) mouse model of AD and gender-matched control (ctl) animals underwent a sequential and standardized PET imaging regimen for direct comparison of [18F]FIBT, [18F]florbetaben, and [11C]PiB. The quantitative PET imaging data were cross-validated with the cerebral Aβ plaque load as quantified ex vivo on histological sections. We found that FIBT (2-(p-methylaminophenyl)-7-(2-[18F]fluoroethoxy)imidazo[2,1-b]benzothiazole) compares favorably to florbetaben as a high-contrasting PET radiopharmaceutical for imaging Aβ pathology. The excellent pharmacokinetics of FIBT in combination with its high-binding affinity towards Aβ resulted in feasible high-contrast imaging of Aβ with high global cortex to cerebellum standard uptake value ratio (SUVR) in 24-month-old tg mice (tg 1.68 ± 0.15 vs. ctl 0.95 ± 0.02). The SUVRs in transgenic versus control animals (SUVRtg/SUVRctl) for FIBT (1.78 ± 0.16) were similar to the ratios as observed in humans (SUVRAD/SUVRctl) for the established gold standard Pittsburgh compound B (PiB) (1.65 ± 0.41). This head-to-head PET tracer comparison study in mice indicated the good imaging properties of [18F]FIBT, such as high initial brain uptake, fast clearance of the brain, and high binding affinity towards Aβ as directly compared to the established amyloid tracers. Moreover, the preclinical study design is recommendable for reliable assessment and comparison of novel radiopharmaceuticals.

7 March 2012 in Molecules
Verified
Journal Article
Open access
PDF file
János MartonJános Marton
János Marton
BGBrita Glaenzel
Brita Glaenzel
JRJulia Roessler
Julia Roessler
DGDaniela Golaszewski
Daniela Golaszewski
GHGjermund Henriksen
Gjermund Henriksen
The route selection and development of a convenient synthesis of 4-carboxy-4-anilidopiperidines is described. Previous routes were hampered by the low yield of the target esters as well as the inability to convert the esters to the required free acids. Considerations for large-scale production led to a modified synthesis that utilised a tert-butyl ester of 4-carboxy-4-anilidopiperidines which resulted in a dramatic increase in the overall yield of the target N-propionylated- 4-anilidopiperidine-4-carboxylic acids and their corresponding methyl esters. These compounds are now available for use as precursors and reference standards, of particular value for the production of 11C and 18F-labelled 4-carboxy-4-anilidopiperidine radiotracers.